FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis
Published version of a preprint
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In breast cancer cells, A-1155463 was found to significantly potentiate BLU9931-induced cell death in a study examining the role of FGFR4-mediated resistance, indicating broader applicability of this combination strategy in solid tumors (Turunen et al., 2019).”
From BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer (2022) · cites this paper as Turunen et al., 2019
In the citing paper
“In breast cancer cells, A-1155463 was found to significantly potentiate BLU9931-induced cell death in a study examining the role of FGFR4-mediated resistance, indicating broader applicability of this combination strategy in solid tumors (Turunen et al., 2019).”
From BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer (2022) · cites this paper as Turunen et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970 · cited 2×
“In cancer, however, non-canonical regulation of YAP expression, localization and activity frequently prevails along with the loss of balancing feed-back mechanisms of normal cellular homeostasis [18, 75, 76].”
BackgroundMechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 1×
“YAP regulators even independent of MST1/2 [17, 66].”
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418 · cited 3×
“In this study, we identified the apoptosis-promoting MST1/2, together with the other Hippo pathway proteins CSNK1D and PRKCI, among the top five FGFR4 substrates based on Z-score in an unbiased in vitro screen.”
BackgroundInfluentialJang, S.-W., Yang, S.-J., Srinivasan, S., & Ye, K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704542200 · Cited by 133
Research works printed but not linked: 74
- Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–34. · DOI · Paper page
- Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318–32. · DOI · Paper page
- Weinstein M, Xu X, Ohyama K, Deng CX. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development. 1998;125:3615–23. · DOI · Paper page
- Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. · DOI · Paper page
- Kothari V, Wei I, Shankar S, Kalyana-Sundaram S, Wang L, Ma LW, et al. Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov. 2013;3:280–93. · DOI
- Tucker JA, Klein T, Breed J, Breeze AL, Overman R, Phillips C, et al. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. Structure. 2014;22:1764–74. · DOI
- Lesca E, Lammens A, Huber R, Augustin M. Structural analysis of the human fibroblast growth factor receptor 4 kinase. J Mol Biol. 2014;426:3744–56. · DOI
- Huang Z, Tan L, Wang H, Liu Y, Blais S, Deng J, et al. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors. ACS Chem Biol. 2015;10:299–309. · DOI
- Mo C, Zhang Z, Guise CP, Li X, Luo J, Tu Z, et al. 2-aminopyrimidine derivatives as new selective fibroblast growth factor receptor 4 (FGFR4) inhibitors. ACS Med Chem Lett. 2017;8:543–8. · DOI
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. · DOI · Paper page
- Pfeffer CM, Singh ATK. Apoptosis: a target for anticancer therapy. Int J Mol Sci. 2018;19:pii: E448. · DOI · Paper page
- Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002;62:840–7.
- Sugiyama N, Varjosalo M, Meller P, Lohi J, Hyytiäinen M, Kilpinen S, et al. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Cancer Res. 2010;70:7851–61. · DOI · Paper page
- Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013;19:809–20. · DOI
- Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation. Clin Cancer Res. 2009;15:2058–66. · DOI · Paper page
- Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, et al. Intrinsic subtype switching and acquired ERBB2/HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol. 2017;3:666–71. · DOI · Paper page
- Hauri S, Wepf A, van Drogen A, Varjosalo M, Tapon N, Aebersold R, et al. Interaction proteome of human Hippo signaling: modular control of the co-activator YAP1. Mol Syst Biol. 2013;9:713. · DOI · Paper page
- Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13:63–79. · DOI · Paper page
- Galan JA, Avruch J. MST1/MST2 protein kinases: regulation and physiologic roles. Biochemistry. 2016;55:5507–19. · DOI
- Graves JD, Gotoh Y, Draves KE, Ambrose D, Han DK, Wright M, et al. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J. 1998;17:2224–34. · DOI · Paper page
- Ura S, Masuyama N, Graves JD, Gotoh Y. Caspase cleavage of MST1 promotes nuclear translocation and chromatin condensation. Proc Natl Acad Sci USA. 2001;98:10148–53. · DOI · Paper page
- Graves JD, Draves KE, Gotoh Y, Krebs EG, Clark EA. Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis. J Biol Chem. 2001;276:14909–15. · DOI · Paper page
- Lee KK, Ohyama T, Yajima N, Tsubuki S, Yonehara S. MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation. J Biol Chem. 2001;276:19276–85. · DOI · Paper page
- Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog. 2007;46:865–71. · DOI · Paper page
- Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009;16:425–38. · DOI · Paper page
- Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA. 2010;107:1437–42. · DOI · Paper page
- Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA. 2010;107:1431–6. · DOI · Paper page
- Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res. 1993;53:627–35.
- Hagel M, Miduturu C, Sheets M, Rubin N, Weng W, Stransky N, et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 2015;5:424–37. · DOI · Paper page
- Fan F, He Z, Kong LL, Chen Q, Yuan Q, Zhang S, et al. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci Transl Med. 2016;8:352ra108. · DOI · Paper page
- Bi W, Xiao L, Jia Y, Wu J, Xie Q, Ren J, et al. c-Jun N-terminal kinase enhances MST1-mediated pro-apoptotic signaling through phosphorylation at serine 82. J Biol Chem. 2010;285:6259–64. · DOI
- Varjosalo M, Björklund M, Cheng F, Syvanen H, Kivioja T, Kilpinen S, et al. Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. Cell. 2008;133:537–48. · DOI · Paper page
- Sugiyama N, Varjosalo M, Meller P, Lohi J, Chan KM, Zhou Z, et al. FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex. Proc Natl Acad Sci USA. 2010;107:15786–91. · DOI
- Tatti O, Vehviläinen P, Lehti K, Keski-Oja J. MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp Cell Res. 2008;314:2501–14. · DOI
- von Nandelstadh P, Grönholm M, Moza M, Lamberg A, Savilahti H, Carpen O. Actin-organising properties of the muscular dystrophy protein myotilin. Exp Cell Res. 2005;310:131–9. · doi:10.1016/j.yexcr.2005.06.027
- von Nandelstadh P, Gucciardo E, Lohi J, Li R, Sugiyama N, Carpen O, et al. Actin-associated protein palladin promotes tumor cell invasion by linking extracellular matrix degradation to cell cytoskeleton. Mol Biol Cell. 2014;25:2556–70. · DOI · Paper page
- Lehti K, Lohi J, Juntunen MM, Pei D, Keski-Oja J. Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. J Biol Chem. 2002;277:8440–8. · DOI · Paper page
- Zhou H, Ye M, Dong J, Corradini E, Cristobal A, Heck AJ, et al. Robust phosphoproteome enrichment using monodisperse microsphere-based immobilized titanium (IV) ion affinity chromatography. Nat Protoc. 2013;8:461–80. · DOI · Paper page
- Taus T, Kocher T, Pichler P, Paschke C, Schmidt A, Henrich C, et al. Universal and confident phosphorylation site localization using phosphoRS. J Proteome Res. 2011;10:5354–62. · DOI · Paper page
- Wang C, Turunen SP, Kummu O, Veneskoski M, Lehtimäki J, Nissinen AE, et al. Natural antibodies of newborns recognize oxidative stress-related malondialdehyde acetaldehyde adducts on apoptotic cells and atherosclerotic plaques. Int Immunol. 2013;25:575–87. · DOI
- Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014;4:5193.
- Tatti O, Arjama M, Ranki A, Weiss SJ, Keski-Oja J, Lehti K. Membrane-type-3 matrix metalloproteinase (MT3-MMP) functions as a matrix composition-dependent effector of melanoma cell invasion. PLoS ONE. 2011;6:e28325. · DOI · Paper page
- Tatti O, Gucciardo E, Pekkonen P, Holopainen T, Louhimo R, Repo P, et al. MMP16 mediates a proteolytic switch to promote cell-cell adhesion, collagen alignment, and lymphatic invasion in melanoma. Cancer Res. 2015;75:2083–94. · DOI · Paper page
- Rantanen V, Valori M, Hautaniemi S. Anima: modular workflow system for comprehensive image data analysis. Front Bioeng Biotechnol. 2014;2:25. · DOI
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4. · DOI · Paper page
- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. · DOI · Paper page
- Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7. · DOI · Paper page
- Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215. · DOI · Paper page
- Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P, et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 2007;67:11368–76. · DOI
- Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ, et al. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene. 2010;29:1543–52. · DOI
- Ulaganathan VK, Sperl B, Rapp UR, Ullrich A. Germline variant FGFR4p.G388R exposes a membrane-proximal STAT3 binding site. Nature. 2015;528:570–4. · DOI
- Praskova M, Xia F, Avruch J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol. 2008;18:311–21. · DOI · Paper page
- Romano D, Matallanas D, Weitsman G, Preisinger C, Ng T, Kolch W. Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 2010;70:1195–203. · DOI
- Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474:179–83. · DOI · Paper page
- Hata Y, Timalsina S, Maimaiti S. Okadaic acid: a tool to study the hippo pathway. Mar Drugs. 2013;11:896–902. · DOI
- Tiong KH, Tan BS, Choo HL, Chung FF, Hii LW, Tan SH, et al. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget. 2016;7:57633–50. · DOI
- McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, et al. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma. Oncogene. 2018;37:2630–44. · DOI
- Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. 2019;16:105–22. · DOI · Paper page
- Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J. 2004;381:453–62. · DOI · Paper page
- Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, et al. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell. 2003;113:507–17. · DOI · Paper page
- Pefani DE, Tognoli ML, Pirincci Ercan D, Gorgoulis V, O’Neill E. MST2 kinase suppresses rDNA transcription in response to DNA damage by phosphorylating nucleolar histone H2B. EMBO J. 2018; 37:pii: e98760. · DOI
- Ye T, Wei X, Yin T, Xia Y, Li D, Shao B, et al. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res Treat. 2014;143:435–46. · DOI
- Boggiano JC, Vanderzalm PJ, Fehon RG. Tao-1 phosphorylates Hippo/MST kinases to regulate the Hippo-Salvador-Warts tumor suppressor pathway. Dev Cell. 2011;21:888–95. · DOI · Paper page
- Poon CL, Lin JI, Zhang X, Harvey KF. The sterile 20-like kinase Tao-1 controls tissue growth by regulating the Salvador-Warts-Hippo pathway. Dev Cell. 2011;21:896–906. · DOI · Paper page
- Zhao S, Yin J, Zhou L, Yan F, He Q, Huang L, et al. Hippo/MST1 signaling mediates microglial activation following acute cerebral ischemia-reperfusion injury. Brain Behav Immun. 2016;55:236–48. · DOI
- Xiao L, Chen D, Hu P, Wu J, Liu W, Zhao Y, et al. The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J Neurosci. 2011;31:9611–9. · DOI · Paper page
- Liu W, Wu J, Xiao L, Bai Y, Qu A, Zheng Z, et al. Regulation of neuronal cell death by c-Abl-Hippo/MST2 signaling pathway. PLoS ONE. 2012;7:e36562. · DOI
- O’Neill E, Kolch W. Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle. 2005;4:365–7. · DOI
- Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 2011;286:6253–61. · DOI · Paper page
- Servas C, Kiehlmeier S, Hach J, Gross R, Gotz C, Montenarh M. The mammalian STE20-like kinase 1 (MST1) is a substrate for the apoptosis inhibiting protein kinase CK2. Cell Signal. 2017;36:163–75. · DOI
- Glantschnig H, Rodan GA, Reszka AA. Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J Biol Chem. 2002;277:42987–96. · DOI · Paper page
- Chen Q, Zhang N, Xie R, Wang W, Cai J, Choi KS, et al. Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes Dev. 2015;29:1285–97. · DOI · Paper page
- Rizvi S, Yamada D, Hirsova P, Bronk SF, Werneburg NW, Krishnan A, et al. A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma. J Biol Chem. 2016;291:8031–47. · DOI · Paper page
- Hua G, Lv X, He C, Remmenga SW, Rodabough KJ, Dong J, et al. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene. 2016;35:2247–65. · DOI · Paper page
Cited by
BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer
Ramesh, P., Di Franco, S., Atencia Taboada, L., Zhang, L., Nicotra, A., Stassi, G., & Medema, J. P. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110374 · Cited by 26
Metadata
- Authors
- Turunen, S. P., von Nandelstadh, P., Öhman, T., Gucciardo, E., Seashore-Ludlow, B., Martins, B., Rantanen, V., Li, H., Höpfner, K., Östling, P., Varjosalo, M., & Lehti, K.
- Venue
- Cell Death & Differentiation
- Published
- 2019-03-22
- Volume
- 26
- Issue
- 12
- Pages
- 2577-2593
- ISSN
- 1350-9047
- 1476-5403
- Cited by
- 47
- References
- 4
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- Funders
- Karolinska Institutet
- Cancerfonden
- Helsingin Yliopisto
- Academy of Finland
- Magnus Ehrnroothin Säätiö
- Medicinska understödsföreningen Liv och hälsa, and the The Finnish Society of Sciences and Letters
- Suomen Akatemia | Terveyden Tutkimuksen Toimikunta
- Knut och Alice Wallenbergs Stiftelse
- Science for Life Laboratory
- Vetenskapsrådet
- Suomen Akatemia | Biotieteiden ja Ympäristön Tutkimuksen Toimikunta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. https://app.cochat.ai/papers/10.1038/s41418-019-0321-x
- The paper
- Turunen, S. P., von Nandelstadh, P., Öhman, T., Gucciardo, E., Seashore-Ludlow, B., Martins, B., Rantanen, V., Li, H., Höpfner, K., Östling, P., Varjosalo, M., & Lehti, K. (2019). FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. Cell Death & Differentiation. https://doi.org/10.1038/s41418-019-0321-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.